Cotargeting AR signaling and cell cycle: A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone sensitive prostate cancer (mHSPC).

Authors

• William Kelly

Publication/Presentation Date

2-2018

Volume

36

Issue

6

Published In/Presented At

DOI: 10.1200/JCO.2018.36.6_suppl.251

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article